+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Artemisinin Combination Therapy Market by Active Ingredient, Dosage Form, End User, Distribution Channel, Patient Group - Global Forecast to 2030- Product Image
Artemisinin Combination Therapy Market by Active Ingredient, Dosage Form, End User, Distribution Channel, Patient Group - Global Forecast to 2030- Product Image
Sale

Artemisinin Combination Therapy Market by Active Ingredient, Dosage Form, End User, Distribution Channel, Patient Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6013910
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Artemisinin Combination Therapy Market grew from USD 362.34 million in 2024 to USD 386.40 million in 2025. It is expected to continue growing at a CAGR of 6.52%, reaching USD 529.39 million by 2030.

Shaping the Future of Malaria Treatment with Artemisinin Combination Therapy

Malaria continues to challenge public health systems worldwide, driving the evolution of therapeutic approaches that combine efficacy with safety and accessibility. Artemisinin Combination Therapy represents a cornerstone in controlling and treating Plasmodium falciparum infections, offering enhanced parasite clearance and reduced risk of resistance due to its dual-mechanism design. This introduction sets the stage for a nuanced exploration of how ACT has reshaped malaria treatment paradigms and why stakeholders across healthcare, policy, and manufacturing sectors are prioritizing its development and distribution.

As demand for robust antimalarial strategies escalates, so does the complexity of the supply chain, regulatory oversight, and R&D investments. This executive summary distills key intelligence on transformative shifts in the ACT landscape, dissects the implications of recent trade policy adjustments, and provides granular segmentation and regional insights. Industry leaders, investors, and decision-makers will find within these pages a clear articulation of current challenges, emerging opportunities, and strategic actions that can drive sustainable growth and global health impact.

Evolving Dynamics Redefine the Artemisinin Combination Therapy Landscape

Over the past decade, the Artemisinin Combination Therapy landscape has undergone profound transformations driven by advances in molecular science, regulatory harmonization, and patient-centric care models. Innovative research into novel artemisinin derivatives and lumefantrine analogues has prompted pharmaceutical companies to refine fixed-dose combinations, ensuring optimal pharmacokinetic profiles while minimizing adverse events. Concurrently, global health initiatives have scaled up subsidy programs and prioritized harmonized dossiers across multiple regulatory agencies, streamlining market entry in regions disproportionately burdened by malaria.

Emerging digital health platforms now enable real-time surveillance of drug efficacy and resistance patterns, informing agile policy responses and fostering collaborative research networks. Strategic partnerships between biotechs, generics manufacturers, and global health organizations have accelerated clinical trial execution and post-market surveillance. Together, these dynamics are redefining value chains, from API synthesis to last-mile delivery. The confluence of scientific innovation, regulatory agility, and integrated health systems is thus steering ACT toward unprecedented reach and resilience.

Decoding the Ripple Effects of 2025 US Tariffs on ACT Supply Chains

In early 2025, the United States implemented a series of tariffs on key active pharmaceutical ingredients, excipients, and packaging materials crucial for Artemisinin Combination Therapy production. These levies have elevated input costs and prompted manufacturers to reassess sourcing strategies. Companies reliant on imports from Asia have navigated logistical bottlenecks and recalibrated procurement to mitigate margin compression. Beyond the immediate cost implications, the tariffs have catalyzed strategic diversification of supply networks, encouraging the development of regional API hubs in alternative geographies.

While some producers have absorbed incremental expenses to maintain price stability in endemic markets, others have accelerated innovation in process chemistry to reduce raw material intensity. Simultaneously, collaboration with local contract development and manufacturing organizations has intensified to safeguard supply continuity. As the 2025 tariff regime persists, stakeholders must balance compliance with cost competitiveness, ensuring that the therapeutic benefits of ACT remain accessible to vulnerable populations.

Unpacking Core Segmentation to Illuminate Market Nuances

A nuanced understanding of segmentation is critical to unlocking market potential. When examining active ingredient variations, the combined potency of Artemether Lumefantrine contrasts with the unique pharmacodynamics of Dihydroartemisinin Piperaquine, while Artesunate Amodiaquine and Artesunate Sulfadoxine Pyrimethamine each address distinct resistance profiles. Formulation diversity further shapes adoption: injectable presentations delivered intramuscularly or intravenously cater to severe case management in clinical environments, whereas oral suspension options in granule sachet or syrup form support caregiver-assisted or self-administered regimens in remote settings. Tablet formats, whether co-packaged kits or fixed-dose combinations, simplify dosing protocols in hospital pharmacies, retail outlets, and growing online pharmacy platforms.

End-user segmentation reveals the differing needs of private versus public clinics, each navigating procurement cycles and funding models. Homecare scenarios range from caregiver-supported administration to self-management by patients, underscoring the necessity for intuitive dosing instructions and stability across diverse climates. Hospital settings, both private and public, demand seamless integration with existing formularies and capacity for bulk distribution. Patient group considerations span adult, geriatric, and pediatric populations, each with unique pharmacokinetic requirements and adherence challenges. By decoding these layers, stakeholders can tailor manufacturing scale, channel strategies, and educational outreach to optimize reach and therapeutic outcomes.

Regional Narratives Driving Artemisinin Combination Therapy Adoption

Geographic intelligence underscores starkly different trajectories across the Americas, Europe Middle East and Africa, and Asia-Pacific. In the Americas, strong public-private partnerships and established supply chains have enabled rapid scale-up of fixed-dose combinations in border regions. Latin American health ministries have championed integrated surveillance systems, allowing for adaptive distribution in both urban and rural contexts. In Europe Middle East and Africa, diverse regulatory landscapes have prompted localized dossier strategies, with some nations fast-tracking registration for formulations that demonstrate superior pediatric safety profiles. Collaborations with non-governmental organizations ensure that remote communities receive injectable and oral suspension variants where infrastructure remains limited.

Asia-Pacific remains a crucible of innovation, driven by a concentration of API manufacturers and dynamic contract research ecosystems. Regional hubs in Southeast Asia are refining process efficiencies for high-purity dihydroartemisinin derivatives, while South Asian pharmaceutical clusters leverage economies of scale to lower cost barriers. Simultaneously, national disease elimination programs in the Asia-Pacific have piloted digital adherence tools, pairing smartphone-based reminders with syrup formulations to improve pediatric compliance. Collectively, these regional narratives reveal that nuanced regulatory engagement, localized manufacturing, and tailored patient enablement are pivotal to advancing Artemisinin Combination Therapy adoption.

Competitive Contours: Key Players Steering ACT Development

Competitive intelligence highlights a landscape where legacy pharmaceutical giants coexist with agile biotech innovators and contract manufacturers. Key players are expanding capacity for high-quality Artemether Lumefantrine and Dihydroartemisinin Piperaquine, investing in process chemistry improvements that reduce solvent usage and shorten reaction times. Meanwhile, emerging firms are carving niches through extended-release oral suspensions and novel intramuscular delivery systems designed to enhance bioavailability and patient adherence.

Strategic alliances have become commonplace, with multinational organizations partnering with regional manufacturers to secure exclusive supply agreements and co-development opportunities. Intellectual property licensing deals facilitate technology transfer, while joint ventures focus on fortifying distribution networks in underserved areas. Beyond product development, some companies are investing in digital platforms that deliver dosing reminders and telemedicine support, fostering deeper engagement with end users and healthcare providers. These multifaceted strategies underscore how competitive positioning hinges on both technical innovation and ecosystem collaboration.

Strategic Imperatives for Leaders in Artemisinin Combination Therapy

Industry leaders must embrace a multi-pronged approach to sustain growth and public health impact. Prioritizing supply chain resilience through regional API diversification and strategic partnerships can mitigate the ongoing effects of trade policy volatility. Investment in next-generation formulations-such as long-acting injectables or taste-masked pediatric suspensions-will differentiate portfolios and address unmet clinical needs. Engaging proactively with regulatory authorities to harmonize registration dossiers across multiple jurisdictions can accelerate time to market and ensure consistency in quality standards.

Furthermore, forging alliances with global health agencies and local NGOs will bolster distribution in hard-to-reach communities, while digital adherence solutions can enhance patient outcomes and generate real-world data for pharmacovigilance. Marketing strategies should align with patient group nuances, offering tailored educational materials for adult, geriatric, and pediatric cohorts. Finally, adopting sustainable manufacturing practices by minimizing waste and energy consumption will strengthen corporate responsibility profiles and resonate with increasingly environmentally conscious stakeholders.

Robust Research Protocols Underpinning Market Insights

This analysis is grounded in a rigorous mixed-methods research design. Primary data were collected through structured interviews with C-level executives, clinical experts, and procurement specialists across endemic and non-endemic regions. Secondary research encompassed peer-reviewed journals, public health reports, and regulatory filings, ensuring a comprehensive synthesis of scientific and policy developments. Data triangulation techniques validated insights across sources, while thematic coding provided clarity on emerging trends and challenges.

Quantitative inputs were derived from shipment records, industry financial disclosures, and tolerance studies, enabling a granular view of product flows and cost structures. Qualitative assessments captured stakeholder perspectives on resistance management, formulation preferences, and distribution bottlenecks. This robust methodology underpins the confidence in the strategic conclusions and actionable recommendations presented throughout this executive summary.

Synthesizing Insights to Navigate the ACT Frontier

The journey through Artemisinin Combination Therapy’s evolving terrain reveals that innovation, collaboration, and strategic agility are essential to meeting global health imperatives. From the nuanced interplay of active ingredient formulations and dosage forms to the adaptive responses required by shifting trade policies, the ability to integrate segmentation insights with regional dynamics defines competitive edge. Key players are harnessing R&D breakthroughs, forging cross-sector alliances, and pioneering digital solutions to elevate patient outcomes and streamline supply chains.

As the field advances, stakeholders who align their strategies with localized needs, embrace sustainable practices, and navigate regulatory complexities will shape the next wave of growth and impact. This synthesis of intelligence offers a foundation for informed decision-making, inspiring confidence in the path forward for Artemisinin Combination Therapy advocates worldwide.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Active Ingredient
    • Artemether Lumefantrine
    • Artesunate Amodiaquine
    • Artesunate Sulfadoxine Pyrimethamine
    • Dihydroartemisinin Piperaquine
  • Dosage Form
    • Injectable
      • Intramuscular
      • Intravenous
    • Oral Suspension
      • Granule Sachet
      • Syrup
    • Tablet
      • Co Packaged
      • Fixed Dose Combination
  • End User
    • Clinics
      • Private
      • Public
    • Homecare
      • Caregiver Assisted
      • Self Administration
    • Hospitals
      • Private
      • Public
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Patient Group
    • Adult
    • Geriatric
    • Pediatric
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Novartis AG
  • Sanofi SA
  • Cipla Limited
  • Viatris, Inc.
  • Ipca Laboratories Ltd.
  • Kunming Pharmaceutical Corp.
  • Guilin Pharmaceutical Co., Ltd.
  • Shin Poong Pharmaceutical Co., Ltd.
  • Qilu Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Artemisinin Combination Therapy Market, by Active Ingredient
8.1. Introduction
8.2. Artemether Lumefantrine
8.3. Artesunate Amodiaquine
8.4. Artesunate Sulfadoxine Pyrimethamine
8.5. Dihydroartemisinin Piperaquine
9. Artemisinin Combination Therapy Market, by Dosage Form
9.1. Introduction
9.2. Injectable
9.2.1. Intramuscular
9.2.2. Intravenous
9.3. Oral Suspension
9.3.1. Granule Sachet
9.3.2. Syrup
9.4. Tablet
9.4.1. Co Packaged
9.4.2. Fixed Dose Combination
10. Artemisinin Combination Therapy Market, by End User
10.1. Introduction
10.2. Clinics
10.2.1. Private
10.2.2. Public
10.3. Homecare
10.3.1. Caregiver Assisted
10.3.2. Self Administration
10.4. Hospitals
10.4.1. Private
10.4.2. Public
11. Artemisinin Combination Therapy Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Artemisinin Combination Therapy Market, by Patient Group
12.1. Introduction
12.2. Adult
12.3. Geriatric
12.4. Pediatric
13. Americas Artemisinin Combination Therapy Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Artemisinin Combination Therapy Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Artemisinin Combination Therapy Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Novartis AG
16.3.2. Sanofi SA
16.3.3. Cipla Limited
16.3.4. Viatris, Inc.
16.3.5. Ipca Laboratories Ltd.
16.3.6. Kunming Pharmaceutical Corp.
16.3.7. Guilin Pharmaceutical Co., Ltd.
16.3.8. Shin Poong Pharmaceutical Co., Ltd.
16.3.9. Qilu Pharmaceutical Co., Ltd.
16.3.10. Sun Pharmaceutical Industries Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ARTEMISININ COMBINATION THERAPY MARKET MULTI-CURRENCY
FIGURE 2. ARTEMISININ COMBINATION THERAPY MARKET MULTI-LANGUAGE
FIGURE 3. ARTEMISININ COMBINATION THERAPY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ARTEMISININ COMBINATION THERAPY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ARTEMISININ COMBINATION THERAPY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ARTEMISININ COMBINATION THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTESUNATE SULFADOXINE PYRIMETHAMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY GRANULE SACHET, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY SYRUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CO PACKAGED, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FIXED DOSE COMBINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PRIVATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PUBLIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CAREGIVER ASSISTED, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PRIVATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PUBLIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 69. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
TABLE 70. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 71. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 72. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2030 (USD MILLION)
TABLE 73. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 74. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 76. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 77. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 78. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 80. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
TABLE 81. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 82. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 83. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2030 (USD MILLION)
TABLE 84. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 85. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 87. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 88. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 89. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 132. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 134. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 136. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
TABLE 137. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 138. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 139. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2030 (USD MILLION)
TABLE 140. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 141. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 143. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 144. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 145. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 147. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
TABLE 148. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 149. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 150. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2030 (USD MILLION)
TABLE 151. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 152. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 154. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 155. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 156. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 165. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 166. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 167. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 169. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
TABLE 170. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 171. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 172. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2030 (USD MILLION)
TABLE 173. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 174. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 176. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 177. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 178. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 180. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
TABLE 181. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 182. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 183. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2030 (USD MILLION)
TABLE 184. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 185. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 187. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 188. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 189. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 194. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 198. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 199. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 200. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2030 (USD MILLION)
TABLE 206. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 207. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 209. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 210. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 211. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 213. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
TABLE 214. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 215. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 216. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2030 (USD MILLION)
TABLE 217. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 218. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 220. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 221. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 222. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 224. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
TABLE 225. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 226. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 227. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2030 (USD MILLION)
TABLE 228. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 229. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 231. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 232. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 233. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 235. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
TABLE 236. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 237. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 238. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2030 (USD MILLION)
TABLE 239. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 240. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 242. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 243. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 244. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 246. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
TABLE 247. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 248. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 249. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2030 (USD MILLION)
TABLE 250. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 251. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 253. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 254. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 255. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 257. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
TABLE 258. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 259. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 260. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2030 (USD MILLION)
TABLE 261. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 262. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 263. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 264. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 265. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 266. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 267. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 268. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
TABLE 269. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 270. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 271. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2030 (USD MILLION)
TABLE 272. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 273. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 275. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 276. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 277. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 279. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
TABLE 280. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 281. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 282. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2030 (USD MILLION)
TABLE 283. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 284. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 285. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 286. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 287. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 288. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 290. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
TABLE 291. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 292. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 293. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2030 (USD MILLION)
TABLE 294. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 295. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 296. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 297. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 298. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 299. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 300. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 301. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
TABLE 302. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 303. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 304. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2030 (USD MILLION)
TABLE 305. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 306. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 307. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 308. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2030 (U

Companies Mentioned

The companies profiled in this Artemisinin Combination Therapy market report include:
  • Novartis AG
  • Sanofi SA
  • Cipla Limited
  • Viatris, Inc.
  • Ipca Laboratories Ltd.
  • Kunming Pharmaceutical Corp.
  • Guilin Pharmaceutical Co., Ltd.
  • Shin Poong Pharmaceutical Co., Ltd.
  • Qilu Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages196
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 386.4 Million
Forecasted Market Value ( USD ) by 2030 $ 529.39 Million
Compound Annual Growth Rate6.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Artemisinin Combination Therapy Market Size, Share and Trends Analysis Report by Type (Artemether+Lumefantrine, Artesunate+Amodiaquine), and Region 2024-2030 - Product Image

Artemisinin Combination Therapy Market Size, Share and Trends Analysis Report by Type (Artemether+Lumefantrine, Artesunate+Amodiaquine), and Region 2024-2030

  • Report
  • 100 Pages
  • Global
From
Artemisinin Combination Therapy - Global Strategic Business Report - Product Image

Artemisinin Combination Therapy - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Artemisinin Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application - Product Image

Artemisinin Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application

  • Report
  • 75 Pages
  • Global
From
Artemisinin (CAS 63968-64-9) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Artemisinin (CAS 63968-64-9) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Hepatitis B Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Hepatitis B Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 181 Pages
  • Global
From

About the Artemisinin Market

Artemisinin is a drug used to treat a variety of infectious diseases, including malaria, schistosomiasis, and filariasis. It is derived from the plant Artemisia annua, and is used in combination with other drugs to increase its effectiveness. Artemisinin is a potent antimalarial drug, and is the most effective treatment for malaria. It is also used to treat other parasitic infections, such as schistosomiasis and filariasis. Artemisinin is available in a variety of forms, including tablets, capsules, and injections. It is also available in combination with other drugs, such as mefloquine, piperaquine, and doxycycline. The drug is generally well tolerated, with few side effects. The Artemisinin market is highly competitive, with many companies offering the drug in various forms. Some of the companies in the market include Novartis, Sanofi, GlaxoSmithKline, Cipla, and Ranbaxy. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.